![](https://i-invdn-com.investing.com/news/news_six_pile_108x81.jpg)
![](https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg)
The European Hematology Association (EHA) Hybrid Congress is the most important gathering of the hematology area in
“I am delighted to showcase the strength and progress of Ascentage Pharma in hematology at this year’s congress, especially the therapeutic potential and clinical value of its drug candidates in chronic myeloid leukemia (CML),
The 5 research to be offered at EHA 2024 are as follows:
- Olverembatinib
Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Patients (Pts) with Heavily Pretreated Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph º ALL)
¢ Abstract#: P722
¢ Presentation Type: Poster presentation
¢ Topic: Chronic myeloid leukemia “ Clinical
¢ Date & Time:
¢ Presenting Author: Dr. Elias Jabbour, The University of Texas MD Anderson Cancer Center
Combination of Third Generation TKI Olverembatinib and Chemotherapy or Blinatumomab for New Diagnosed Adult Ph+ ALL Patients
¢ Abstract#: P427
¢ Presentation Type: Poster presentation
¢ Topic: Acute lymphoblastic leukemia “ Clinical
¢ Date & Time:
¢ Presenting Author: Junjie Chen, Nanfang Hospital, Southern Medical University
Patient Reported Outcomes in Adults with TKI-Resistant Chronic Myeloid Leukemia Receiving Olverembatinib-Therapy
¢ Abstract#: P1862
¢ Presentation Type: e-Poster presentation
¢ Topic: Chronic myeloid leukemia “ Clinical
¢ Date & Time: Friday June 14, 2024,
¢ Presenting Author: Lu Yu, Peking University People’s Hospital
- Lisaftoclax
Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (Pts) with Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis
¢ Abstract#: P917
¢ Presentation Type: Poster presentation
¢ Topic: Myeloma and different monoclonal gammopathies “ Clinical
¢ Date & Time:
¢ Presenting Author: Dr. Sikander Ailawadhi, Mayo Clinic Florida
Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Improves Chronic Kidney Disease- (CKD)-Induced Hemoglobin (HB) Insufficiency in Preclinical Models of Anemia
¢ Abstract#: P1550
¢ Presentation Type: Poster presentation
¢ Topic: Enzymopathies, membranopathies and different anemias
¢ Date & Time:
¢ Presenting Author: Dr. Eric Liang, Ascentage Pharma Group Inc.
About Ascentage Pharma
Ascentage Pharma (6855.HK) is a globally centered biopharmaceutical firm engaged in growing novel therapies for cancers, power hepatitis B, and age-related illnesses. On
Ascentage Pharma focuses on growing therapeutics that inhibit protein-protein interactions to revive apoptosis, or programmed cell dying. The firm has constructed a pipeline of 9 medical drug candidates, together with novel, extremely potent Bcl-2, and twin Bcl-2/Bcl-xL inhibitors, in addition to candidates aimed toward IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma can also be the one firm on this planet with energetic medical packages focusing on all three identified lessons of key apoptosis regulators. The firm is conducting greater than 40 Phase I/II medical trials, together with 5 international registrational section III research, within the US,
Olverembatinib, the corporate’s core drug candidate developed for the therapy of drug-resistant power myeloid leukemia (CML) and the corporate’s first accredited product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the
Leveraging its strong R&D capabilities, Ascentage Pharma has constructed a portfolio of world mental property rights and entered into international partnerships with quite a few famend biotechnology and pharmaceutical corporations and analysis institutes equivalent to UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca (NASDAQ:). The firm has constructed a proficient workforce with international expertise within the discovery and improvement of revolutionary medication and is establishing its world-class business manufacturing and Sales & Marketing groups. One pivotal goal of Ascentage Pharma is to repeatedly strengthen its R&D capabilities and speed up its medical improvement packages, with a purpose to fulfil its mission of addressing unmet medical wants in
Forward-Looking Statements
The forward-looking statements made on this article relate solely to the occasions or info as of the date on which the statements are made on this article. Except as required by legislation, Ascentage Pharma undertakes no obligation to replace or revise publicly any forward-looking statements, whether or not because of new info, future occasions, or in any other case, after the date on which the statements are made or to replicate the incidence of unanticipated occasions. You ought to learn this text fully and with the understanding that our precise future outcomes or efficiency could also be materially completely different from what we count on. In this text, statements of, or references to, our intentions or these of any of our Directors or our Company are made as of the date of this text. Any of those intentions might alter in gentle of future improvement.
MoneyMaker FX EA Trading Robot
powered by qhost365.com
Investing.com